E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
non-cardiac major surgery |
|
E.1.1.1 | Medical condition in easily understood language |
non-cardiac major surgery |
|
E.1.1.2 | Therapeutic area | Not possible to specify |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10042609 |
E.1.2 | Term | Surgery |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Evaluate the effectiveness of perioperative administration of corticosteroid to reduce postoperative morbidity and mortality in patients undergoing major non-cardiac surgery |
|
E.2.2 | Secondary objectives of the trial |
- To evaluate the safety (clinical adverse events, especially glycaemic deregulation) of corticosteroids administration in patients undergoing major non-cardiac surgery - To evaluate the effect of corticosteroid administration on the incidence of postoperative infections, wound healing - To evaluate the effect of corticosteroid administration on postoperative gastrointestinal dysfunction - To evaluate the effect of corticosteroid administration on the duration of hospital stay
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Major surgery (> 90 minutes and realized under general anesthesia) of the abdomen, pelvis, thorax, face/neck, vascular surgery in a patient older than 65 years Or Major surgery (> 90 minutes and realized under general anesthesia) of the abdomen, pelvis, thorax, face/neck, vascular surgery in a patient older than 50 years and presenting one of the following criteria o Presence of a defined risk factor for cardiac or respiratory disease (exercise tolerance equivalent to 6 metabolic equivalents or less) o Medical history of stroke o Moderate to severe renal impairment (clearance of creatinine ≤ 30 mll/L) o Active smoking o Averaged observed blood losses over 500 ml o Emergency surgery
|
|
E.4 | Principal exclusion criteria |
- Pregnant women, Minors, Adults under guardianship or trusteeship - Treatment with systemic corticosteroids at a dose > 5 mg.day-1 of equivalent prednisolone in the previous 3 months - Patients with chronic renal failure (clearance of creatinine < 10 ml/min) - Patients for which death is deemed imminent and inevitable or patients with an underlying disease process with a life expectancy of less than 1 month - Patient with preoperative shock (defined by the need for vasoactive drugs before surgery) - Acute Pulmonary edema in the last 7 days - Active bacterial or viral infection - Allergy to the intravenous formulation of dexamethasone - Uncontrolled psychotic disorder (acute or chronical)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Composite outcome (all-cause mortality and major postoperative complications) within 14 days after surgery, at least one item among the following: - Postoperative sepsis, severe sepsis, septic shock - Postoperative pulmonary complication (postoperative pneumonia, need for invasive ventilation and/or noninvasive ventilation for respiratory failure)
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- All-cause mortality 28 days after randomization - Hospital free-days at 28 days - Surgical complications according to the Clavien-Dindo classification within 28 days following randomization - Duration of hospital stay (patients who will be outside the hospital but in other types of health care facilities at day 28 will be considered to have been discharged home) - Unplanned admission or readmission to critical care (within 28 days following randomization) - Proportion of patients who experience postoperative morbidity (all defined according to consensus criteria or universal definitions within 7 days after surgery) including: o renal dysfunction (according to the KDIGO criteria: Appendix 2), o cardiac complications (acute heart failure, myocardial infarction), o infectious complications (especially surgical site infection), o gastrointestinal dysfunction - Duration of invasive mechanical ventilation, Duration of non-invasive mechanical ventilation - SOFA score at day 1 and day 3 after surgery - Percentage of patients with new organ dysfunction (not present at randomization) - Blood levels of CRP - Proportion of patients who experienced adverse events, especially hyperglycaemia, healing impairment within 7 days after surgery
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 32 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 25 |
E.8.9.1 | In the Member State concerned days | |